These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 15898000)

  • 1. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis.
    Tewary P; Jain M; Sahani MH; Saxena S; Madhubala R
    J Infect Dis; 2005 Jun; 191(12):2130-7. PubMed ID: 15898000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P; Sukumaran B; Saxena S; Madhubala R
    Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis.
    Tewary P; Saxena S; Madhubala R
    Vaccine; 2006 Mar; 24(13):2409-16. PubMed ID: 16413950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani.
    Sharma A; Madhubala R
    J Immunol; 2009 Dec; 183(12):7719-31. PubMed ID: 19933862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis.
    Rafati S; Zahedifard F; Nazgouee F
    Vaccine; 2006 Mar; 24(12):2169-75. PubMed ID: 16325969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
    Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
    Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani.
    Sukumaran B; Tewary P; Saxena S; Madhubala R
    Vaccine; 2003 Mar; 21(11-12):1292-9. PubMed ID: 12559811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice.
    Rafati S; Zahedifard F; Azari MK; Taslimi Y; Taheri T
    Exp Parasitol; 2008 Mar; 118(3):393-401. PubMed ID: 18093586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.
    Gamboa-León R; Paraguai de Souza E; Borja-Cabrera GP; Santos FN; Myashiro LM; Pinheiro RO; Dumonteil E; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(22):4863-73. PubMed ID: 16635538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
    Daifalla NS; Bayih AG; Gedamu L
    Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.
    Ferreira JH; Gentil LG; Dias SS; Fedeli CE; Katz S; Barbiéri CL
    Vaccine; 2008 Jan; 26(5):677-85. PubMed ID: 18160187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice.
    Zhao HP; Sun JF; Li N; Sun Y; Wang Y; Qiu HJ
    Vet Immunol Immunopathol; 2009 Oct; 131(3-4):158-66. PubMed ID: 19411115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of protective immune responses induced by Toxoplasma gondii dense granule antigen 7 (GRA7) against toxoplasmosis in mice using a prime-boost vaccination strategy.
    Min J; Qu D; Li C; Song X; Zhao Q; Li XA; Yang Y; Liu Q; He S; Zhou H
    Vaccine; 2012 Aug; 30(38):5631-6. PubMed ID: 22789504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK; Naskar K; De T
    Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection.
    Carter KC; Henriquez FL; Campbell SA; Roberts CW; Nok A; Mullen AB; McFarlane E
    Vaccine; 2007 May; 25(22):4502-9. PubMed ID: 17418459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmaniasis: current status of vaccine development.
    Sukumaran B; Madhubala R
    Curr Mol Med; 2004 Sep; 4(6):667-79. PubMed ID: 15357215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced immunogenicity of an anti-caries vaccine encoding a cell-surface protein antigen of Streptococcus mutans by intranasal DNA prime-protein boost immunization.
    Li Y; Jin J; Yang Y; Bian Z; Chen Z; Fan M
    J Gene Med; 2009 Nov; 11(11):1039-47. PubMed ID: 19718694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.